MECP2 and pulmonary fibrosis: Collectively, our data suggest that Mecp2 is essential for the progression of pulmonary fibrosis, and therefore, intratracheal injection of Mecp2 siRNA‐loaded liposomes could be a viable therapeutic approach for pulmonary fibrosis.